KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Halozyme Therapeutics (HALO) over the last 15 years, with Q4 2025 value amounting to $134.2 million.

  • Halozyme Therapeutics' Gains from Investment Securities rose 7208.06% to $134.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $134.6 million, marking a year-over-year increase of 6701.11%. This contributed to the annual value of $134.6 million for FY2025, which is 6701.11% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Gains from Investment Securities of $134.2 million as of Q4 2025, which was up 7208.06% from -$307000.0 recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Gains from Investment Securities ranged from a high of $134.2 million in Q4 2025 and a low of -$2.9 million during Q2 2024
  • For the 5-year period, Halozyme Therapeutics' Gains from Investment Securities averaged around $14.9 million, with its median value being $753000.0 (2022).
  • In the last 5 years, Halozyme Therapeutics' Gains from Investment Securities surged by 274083.19% in 2022 and then tumbled by 2644545.45% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Gains from Investment Securities (Quarter) stood at $1.2 million in 2021, then skyrocketed by 2740.83% to $33.5 million in 2022, then dropped by 8.73% to $30.5 million in 2023, then soared by 155.35% to $78.0 million in 2024, then skyrocketed by 72.08% to $134.2 million in 2025.
  • Its last three reported values are $134.2 million in Q4 2025, -$307000.0 for Q3 2025, and -$2.6 million during Q2 2025.